In one paragraphArticle in Journal of clinical medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
15 authors.
Erdem SüngerDepartment of Medical Oncology, Faculty of Medicine, Istanbul Medipol University, Istanbul 34214, Türkiye.ORCID 0000-0001-5194-1634 Harun MuğluDepartment of Medical Oncology, Bagcilar Training and Research Hospital, University of Health Sciences, Istanbul 34214, Türkiye.ORCID 0000-0001-9584-0827 Mehmet Haluk YücelDepartment of Medical Oncology, Faculty of Medicine, Istanbul Medipol University, Istanbul 34214, Türkiye.ORCID 0000-0001-6880-7204 Ebru Engin DelipoyrazDepartment of Medical Oncology, Faculty of Medicine, Istanbul Medipol University, Istanbul 34214, Türkiye.ORCID 0000-0003-4979-3630 Maral Martin MıldanoğluDepartment of Medical Oncology, Faculty of Medicine, Istanbul Medipol University, Istanbul 34214, Türkiye.ORCID 0000-0002-4587-0726 Hakan ÖzçelikDepartment of Medical Oncology, Faculty of Medicine, Istanbul Medipol University, Istanbul 34214, Türkiye.
Sena FidanDepartment of Medical Oncology, Faculty of Medicine, Istanbul Medipol University, Istanbul 34214, Türkiye.ORCID 0000-0001-8895-296X Cihat TerzioğluDepartment of Medical Oncology, Faculty of Medicine, Istanbul Medipol University, Istanbul 34214, Türkiye.
Burçin Çakan DemirelDepartment of Medical Oncology, Faculty of Medicine, Istanbul Medipol University, Istanbul 34214, Türkiye.ORCID 0000-0003-0734-0692 Jamshid HamdardDepartment of Medical Oncology, Faculty of Medicine, Istanbul Medipol University, Istanbul 34214, Türkiye.ORCID 0000-0002-5823-1704 Yasin KutluDepartment of Medical Oncology, Faculty of Medicine, Istanbul Medipol University, Istanbul 34214, Türkiye.ORCID 0000-0003-2184-634X Özgür AçıkgözDepartment of Medical Oncology, Faculty of Medicine, Istanbul Medipol University, Istanbul 34214, Türkiye.ORCID 0000-0003-2715-4002 Aslı ÇakırDepartment of Medical Pathology, Faculty of Medicine, Istanbul Medipol University, Istanbul 34214, Türkiye.
Mesut ŞekerDepartment of Medical Oncology, Faculty of Medicine, Istanbul Medipol University, Istanbul 34214, Türkiye.
Ahmet BiliciDepartment of Medical Oncology, Faculty of Medicine, Istanbul Medipol University, Istanbul 34214, Türkiye.ORCID 0000-0002-0443-6966 Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
HER2-positive breast cancerneoadjuvant therapypathological complete response (pCR)TIPI scoretumor-infiltrating lymphocytes (TILs)
Identifiers
PMID42074920
PMCPMC13116748
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390